Work

Durvalumab in ≥ 3rd-line advanced NSCLC: Updated results from the phase 2 ATLANTIC study.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.9058

Authors: Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, Julien Mazieres, Jhanelle Elaine Gray, Paul Wheatley-Price, Keunchil Park, Ross A. Soo, Yifan Huang, Catherine Wadsworth, Phillip A. Dennis, Naiyer A. Rizvi

Institutions: Fondazione IRCCS Istituto Nazionale dei Tumori, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, CHA University Bundang Medical Center, CHA University, Université Toulouse III - Paul Sabatier, Centre Hospitalier Universitaire de Toulouse, Moffitt Cancer Center, University of Ottawa, Ottawa Hospital Research Institute, Samsung Medical Center, Sungkyunkwan University, National University Cancer Institute, Singapore, National University Hospital, AstraZeneca (United Kingdom), Columbia University Irving Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891029537

Cites:

Cited by: 3

Related to: 10